Home / Companies / Halozyme Therapeutics, Inc. / 1 May 2025
Halozyme Therapeutics, Inc.: meeting of 1 May 2025
Votes reported on Form N-PX, item by item
696 Form N-PX filers reported votes at the Halozyme Therapeutics, Inc. meeting of 1 May 2025. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 96.0% of reported votes for; 18 filers withheld from or voted against at least one nominee.
1,002 vote records from 236 filers. 4 of the 234 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
1,117 vote records from 689 filers. 46 of the 665 filers that marked the item either way voted against management. 24 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
502 vote records from 236 filers. 2 of the 234 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.
How the largest families voted
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Halozyme Therapeutics, Inc. meeting?
696 Form N-PX filers reported votes at the meeting of 1 May 2025. On say-on-pay, 46 of 665 voted against management (6.9%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Halozyme Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Halozyme Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Halozyme Therapeutics, Inc. with a meeting date within three days of 1 May 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.